The week in pharma: action, reaction and insight – week to July 7, 2023

By Barbara Obstoj-Cardwell. Editor

Among important research news last week, UK pharma major AstraZeneca released the first Phase III data on its lung cancer candidate datopotamab (Dato-DXd). On the regulatory front, US drugmaker Amneal Pharmaceuticals suffered a setback when the US Food and Drug Administration (FDA) issued a complete response letter (CRL) on its Parkinson’s disease candidate IPX203. Also, the FDA handed full approval to Eisai and Biogen's Alzheimer's treatment Leqembi last Thursday following a study that verified the drug's ability to slow cognitive decline in the early stages of the disease, a decision that opened the door for broader Medicare coverage of the treatment. US pharma giant Pfizer acquired $25 million worth of stock in Caribou Biosciences, a gene-editing company, which will help in the development of the latter’s CB-011 in multiple myeloma.

TROPION-Lung01 hits on PFS; lack of details, safety concerns weighing on shares